Clinical trials: Hepatitis C Virus (HCV)
Liver Disease
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
There still remains the question if hepatitis C eradication with all oral therapy will lead to a regression or cure of the low grade lymphoma.
- Trial name
- Optimal (NCT02717949)
- Testing
- sofosbuvir/ledipasvir, sofosbuvir, Ribavirin
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatitis C
Examining Hepatitis C Reinfection Rates in Kenya
The goal of this research project is to build upon the Testing and Linkage to Care for Injecting Drug Users (TLC-IDU) parent study and describe post-cure HCV reinfection in a population of people who inject drugs (PWIDs) in Kenya.
- Trial name
- NCT03564639
- Where
- Kenya
- Volunteers
- 101 people
- Sponsor
- Yale University
Hepatitis C, Hepatitis B
Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication
The estimated global prevalence of hepatitis C (HCV) infection is approximately 3% (170 million individuals). In Canada there are an estimated 240,000 people infected with HCV.
- Trial name
- NCT00188201
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hepatitis C Virus Infection
Implementing HCV Treatment for High-risk Populations in Austin, Texas
Highly-effective, pan-genotypic direct acting antivirals (DAAs) have made elimination of hepatitis C virus (HCV) a real possibility.
- Trial name
- NCT05460130
- Testing
- Simplified Hepatitis C Virus (HCV) Treatment Protocol
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Texas at Austin
Patients Undergoing Routine Health Care, Heart Diseases
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance…
- Conditions
- Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease
- Trial name
- NCT01280825
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Chronic Hepatitis C, Intravenous Drug Usage
Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong
In the current era of highly effective direct acting antiviral (DAA) therapy, the remaining obstacles to elimination of chronic HCV infection are identification of the high-risk groups, linkage to continued care and prevention of…
- Trial name
- NCT03993925
- Where
- Hong Kong
- Volunteers
- 800 people
- Sponsor
- The University of Hong Kong
Acute Hepatitis C, HIV
Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
The purpose of this study is to assess the rate of sustained virological response (SVR) 12 weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in patients with acute hepatitis C genotype1 or 4.
- Trial name
- SAHIV (NCT02886624)
- Testing
- Grazoprevir/Elbasvir
- Where
- 6 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Chronic Hepatitis C
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children.
- Trial name
- NCT00100659
- Testing
- Pegylated Interferon/ribavirin
- Where
- 11 sites in United States
- Volunteers
- 114 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C Virus
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
The purpose of this multicenter, single-arm, combination-drug study, which includes 12 weeks of treatment and 24 weeks of follow-up, is to evaluate the safety, efficacy and pharmacokinetics of ombitasvir/paritaprevir/ritonavir in…
- Trial name
- GIFT-R (NCT02806362)
- Testing
- Ombitasvir/paritaprevir/ritonavir
- Sponsor
- AbbVie
Hepatitis C
T Regulatory Cells in Hepatitis c Infected Patients
Chronic hepatitis C infection is a global worldwide health problem with an increasing burden year-by-year, particularly in areas with a high endemicity like Egypt .
- Trial name
- NCT03186235
- Testing
- Flow cytometry
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Assiut University
Chronic Hepatitis C
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectiveness of valopicitabine alone and…
- Trial name
- NCT00118768
- Testing
- valopicitabine, Pegylated Interferon Alfa
- Where
- 19 sites in United States
- Volunteers
- 175 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Increasing HCV Linkage to Care Among People Who Inject Drugs
Our study will test the effectiveness of a simplified approach to delivering Hepatitis C Virus (HCV) care in a street-based mobile medical clinic among people who inject drugs in increasing treatment initiation, retention, and…
- Trial name
- NCT04741750
- Testing
- Simplified HCV care within a mobile medical unit
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Family Health Centers of San Diego
HEPATITIS C (HCV), Incarceration
Implementing Low-Barrier HCV Treatment in a Jail Setting
The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily.
- Conditions
- HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
- Trial name
- MINMON-J (NCT06953479)
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Lifespan
Hepatocellular Carcinoma, Hepatitis B
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
This is a Phase II study in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
- Trial name
- OUTREACH2 (NCT04710641)
- Testing
- MTL-CEBPA, Sorafenib
- Where
- 2 sites in United States, Singapore
- Volunteers
- 8 people
- Sponsor
- Mina Alpha Limited
Hepatitis C, Compensated Cirrhosis
Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis
To assess efficacy (SVR rate) of MK5172 / MK8742 for 12 weeks without RBV in G1b patients with compensated cirrhosis (Child-Pugh A5 to A6) previously failing first gen. PI or non responders to PR.
- Trial name
- GECOM (NCT02732405)
- Testing
- MK5172 /MK8742
- Volunteers
- 120 people
- Sponsor
- Istituto Clinico Humanitas
Chronic Hepatitis c
Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)
A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)
- Trial name
- NCT05138523
- Testing
- Sofosdac®
- Where
- 4 sites in Algeria
- Volunteers
- 99 people
- Sponsor
- Beker Laboratories
Chronic Hepatitis C Virus, Hepatitis C, Chronic
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
- Conditions
- Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis
- Trial name
- NCT05904470
- Testing
- Bemnifosbuvir, Ruzasvir
- Where
- 51 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C Virus Infection, Liver Transplantation
Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation
Viral infections can profoundly influence alloimmune responses and hamper allograft tolerance induction. Persistent hepatitis C virus (HCV) infection occurs in 50% of liver and 20% of kidney transplant recipients, but the impact…
- Trial name
- NCT00668369
- Testing
- Gradual immunosuppression drug withdrawal.
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Hospital Clinic of Barcelona
NAFLD, Hepatocellular Carcinoma
Utilization of MAsS in Patients Undergoing LT for HCC
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
- Conditions
- NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer
- Trial name
- NCT05184283
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Chronic Hepatitis C Viral Infection
Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.
- Trial name
- NCT01159613
- Testing
- Responders, Non Responders
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Ziv Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.